Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Bücher
Zeitschriften
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
SLX-Digitalkonferenz: Zukunftswerkstatt 2024

Mehr Umsatz mit Top-Kontakten

Am 7. Mai erfahren Sie, wie Vertriebsteams Leadgenerierung, Leadnurturing und Leadstrategien effizient steuern können.
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Public Health Modeling at the Centers for Disease Control and Prevention Kapitel lesen Erstes Kapitel lesen

2013 | OriginalPaper | Buchkapitel

9. Modeling the Impact of New HIV Prevention Technologies in Sub-Saharan Africa

verfasst von : John Stover, Carel Pretorius, Kyeen Andersson

Erschienen in: Operations Research and Health Care Policy

Verlag: Springer New York

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Research has shown that several new technologies can be effective in reducing the transmission of HIV infection. Male circumcision was shown to reduce susceptibility to new infection by about 60% in trials in 2005 and 2007. In 2009, a large scale trial of an HIV vaccine showed some protective benefits. Research results released in 2010 showed effectiveness of oral pre-exposure prophylaxis and topical pre-exposure prophylaxis at levels around 40%. When new technologies become available national policy makers are faced with questions about whether to implement them, how much they will cost and how they should be implemented. Funders face similar questions. We have developed computer models to aid in policy development and planning. These models are intended to investigate questions such as “What will the impact be in terms of infections averted?”, “How much would a new program cost?”, and “Would the new program be cost-effective?” This chapter discusses models for male circumcision, pre-exposure prophylaxis, and HIV vaccines and their applications to inform policy makers.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Jetzt informieren
Vorheriges Kapitel Assessing Prevention for Positives: Cost-Utility Assessment of Behavioral Interventions for Reducing HIV Transmission
Nächstes Kapitel REACH: A Practical HIV Resource Allocation Tool for Decision Makers
Literatur
1.
Garnett G, Wilson DP (2011) Epidemic modeling. Curr Opin HIV AIDS 6:1–140CrossRef
2.
Weiss H, Quigley MA, Hayes RJ (2000) Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis. AIDS 14:2361–2370CrossRef
3.
Buvé A, Carael M, Hayes RB, Auvert B et al. (2001) Multicentre study on factors determining differences in rate of spread of HIV in sub-Saharan Africa: methods and prevalence of HIV infection. AIDS 15(Suppl 4):S5–S14CrossRef
4.
Auvert B, Buvé A, Lagarde E et al. (2001) Male circumcision and HIV infection in four cities in sub-Saharan Africa. AIDS 15(Suppl 4):S31–S40CrossRef
5.
6.
Bailey RC, Moses S, Parker CB et al. (2007) Male circumcision HIV prevention young men in Kisumu, Kenya: a randomized controlled trial. Lancet 369:643–656CrossRef
7.
Gray RH, Kigozi G, Serwdda D et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomized trial. Lancet 359:657–666CrossRef
8.
9.
Nagelkerke NJ, Moses S, de Vlas SJ, Bailey RC (2007) Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa. BMC Infect Dis 7:16CrossRef
10.
Gray RH, Li X, Kigozi G, Serwadda D, Nalugoda F et al. (2007) The impact of male circumcision on HIV incidence and cost per infection prevented: a stochastic simulation model from Rakai, Uganda. AIDS 21:845–850CrossRef
11.
12.
White RG, Glynn JR, Orroth KK, Freeman EE, Bakker R et al. (2008) Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when? AIDS 22:1841–1850CrossRef
13.
Alsallaq R, Abu-Raddad L (2008) Male circumcision is a leading actor behind the differential HIV prevalence in sub-Saharan Africa [Poster MOPE0254]. In: Proceedings of the XVII international AIDS conference, Mexico City, Mexico. http://​www.​aids2008-abstracts.​org/​. Accessed 13 Aug 2009
14.
15.
Auvert B, Marseille E, Korenromp EL, Lloyd-Smith J, Sitta R et al. (2008) Estimating the resources needed and savings anticipated from rollout of adult male circumcision in sub-Saharan Africa. PLoS One 3:e2679. doi:10.​1371/​journal.​pone.​0002679 CrossRef
16.
Bollinger L, Stover J, Musuka G et al. (2009) The cost and impact of male circumcision on HIV/AIDS in Botswana. J Int AIDS Soc 12:7. doi:10.11861/1758-2652-12-7CrossRef
17.
18.
19.
Njeuhmeli E, Forsythe S, Reed J, Opuni M, Bollinger L et al. (2011) Voluntary medical male circumcision: modeling the impact and cost of expanding male circumcision for HIV prevention in eastern and Southern Africa. PLoS Med 8(11):e1001132. doi:http://​10.​1371/​journal.​pmed.​1001132
20.
Grant R (2010) Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and post-exposure prophylaxis. Clin Infect Dis 50:96–101CrossRef
21.
Braitstein P, Brinkhof M, Dabis F, Schechter M, Boulle A et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367:817–824CrossRef
22.
Jahn A, Floyd S, Crampin A, Mwaungulu F, Mvula H et al. (2008) Population level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 371:1603–1611CrossRef
23.
Guay L, Musoke P, Fleming T, Bagenda D, Allen M et al. (1999) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354:795–802
24.
Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168–1174CrossRef
25.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363:2587–2599CrossRef
26.
Pretorius C, Stover J, Bollinger L, Bacaer N, Williams B (2010) Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One 5(11):e13646CrossRef
27.
Bacaer N, Pretorius C, Auvert B (2010) An age-structured model for the potential impact of generalized access to antiretrovirals on the South African HIV epidemic. Bull Math Biol 72:2180–2198. doi:10.​1007/​s11538-010-9535-2 CrossRef
28.
Granich R, Gilks C, Dye C, De Cock K, Williams B (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373:48–57CrossRef
29.
Donnell D, Baeten J, Kiarie J, Thomas K, Stevens W et al. (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375:2092–2098CrossRef
30.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365:493–505. doi:10.​1056/​NEJMoa1105243 CrossRef
31.
Abbas U, Anderson R, Mellors J (2007) Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One 2:e875CrossRef
32.
Abbas U, Glaubius R, Mubayi A, Hood G, Mellors J (2011) Predicting the impact of ART and PrEP with overlapping regiments on HIV transmission and drug resistance in South Africa. Paper # 98LB, Presented at 18th conference on retroviruses and opportunistic infections, Boston
33.
Global report UNAIDS (2010) UNAIDS report on the global AIDS epidemic 2010, Joint United Nations Programme on HIV/AIDS, Geneva
34.
International AIDS Vaccine Initiative Database of AIDS vaccine candidates in clinical trials. International AIDS Vaccine Inititative, New York. www.​iavi.​org. Accessed 28 Mar 2011
35.
Future access to HIV vaccines UNAIDS (2001) Report from a WHO-UNAIDS Consultation, Geneva, 2–3 Oct 2000, 15:W27–W44
36.
Francis DP, Heyward WL, Popovic V, Orozco-Cronin P, Orelind K, Gee C et al. (2003) Candidate HIV/AIDS vaccines: lessons learned from the World’s first phase III efficacy trials. AIDS 17:147–156CrossRef
37.
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209–2220CrossRef
38.
39.
40.
Fonseca MGP, Forsythe S, Menezes A, Vuthoori S, Possas C, Veloso V et al. (2010) Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV. PLoS One 5:e11736CrossRef
41.
42.
International AIDS Vaccine Initiative(a) (2009) Kenya: estimating the potential impact of an AIDS vaccine. Policy Brief 24. International AIDS Vaccine Initiative, New York. http://​www.​iavi.​org. Accessed 12 Feb 2011
43.
Stover J, Bollinger L, Hecht R, Williams C, Roca E (2007) The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff 26:1147–1158CrossRef
44.
Hecht R, Stover J, Bollinger L, Muhib F, Case K, de Ferranti D (2010) Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009–31. Lancet 376:1254–1260CrossRef
45.
Metadaten
Titel
Modeling the Impact of New HIV Prevention Technologies in Sub-Saharan Africa
verfasst von
John Stover
Carel Pretorius
Kyeen Andersson
Copyright-Jahr
2013
Verlag
Springer New York
Buch
Operations Research and Health Care Policy

Print ISBN: 978-1-4614-6506-5

Electronic ISBN: 978-1-4614-6507-2

Copyright-Jahr: 2013

DOI
https://doi.org/10.1007/978-1-4614-6507-2_9

Premium Partner

    Bildnachweise